The ability of a GATA2 inhibitor to suppress several AR-mediated and AR-independent PC driver pathways and to overcome resistance to hormonal therapy opens new treatment opportunities for CRPC patients. The gene discussed is GATA2; the disease is pachyonychia congenita.